In a study utilizing PD-1 inhibitors for NSCLC, Song et al. conducted an analysis of the functional group protein family and gut microbiome metabolism in patients with different PFS (≥ 6 months or < 6 months). Here, PDCD1 is linked to non-small cell lung carcinoma.